Na Cocer Peptides 
25 mau lā aku nei.
Ma waho aʻe o nā kikowaena koʻikoʻi e like me ka metabolic regulation a me ka immune anti-inflammation, hōʻike nā mea peptide i ka waiwai kūʻokoʻa i nā hiʻohiʻona kūikawā e pili ana i ka hoʻopili ʻana i ka maʻi hanu, ka pale ʻana i ka hana cardiovascular, a me ka hoʻomohala ʻana i nā mea hana noiʻi hoʻokolohua, no ko lākou ʻano kiʻekiʻe a me ka hana olaola. Hoʻopau kēia mau noi i nā palena o nā lāʻau kuʻuna, e hāʻawi ana i nā hopena hou no ka mālama ʻana i nā maʻi paʻakikī a me ka noiʻi ʻepekema kumu ma o ka hoʻoponopono ʻana i ka mucosal i manaʻo ʻia i loko o ka ʻōnaehana hanu, ka hoʻoponopono ʻana i nā ala hōʻailona cardiovascular cell, a me ka mana pololei o nā hoʻohālike hoʻokolohua. ʻO kā lākou mau pōmaikaʻi koʻikoʻi - ka kikoʻī kiʻekiʻe kiʻekiʻe, immunogenicity haʻahaʻa, a me ka synthesis maʻamau - e alakaʻi i ka hoʻonui cross-disciplinary o nā peptides mai ka lāʻau lapaʻau i nā noi multidisciplinary.
Kiʻi 1. Hōʻike schematic o ka pane ʻana i ka immune pathologic ma nā alaloa. Source: Proinflammatory Cytokines in Chronic Respiratory Diseases and Their Management (2025).
Wahi noi
1. Pūnaehana Respiratory: Hoʻoponopono Alanui a me ka Hoʻoponopono Hoʻonā
No nā maʻi refractory e like me ka maʻi obstructive pulmonary maʻi (COPD), fibrosis pulmonary, a me ka hānō maʻi, hana nā mea peptide ma o ka anti-inflammation, antioxidation, a me ka hoʻoponopono mucosal.
ʻO ka pale a me ka hoʻoponopono ʻana i ka mucosal ea
Hoʻoikaika nā peptides hoʻoponopono Bronchial i ka hoʻonui ʻana o ka epithelial cell proliferation a me ka synthesis protein junction paʻa ma ka hoʻoulu ʻana i ka epidermal growth factor receptor a me ka hoʻololi ʻana i nā ala ulu kumu-β, hoʻoponopono i ka pōʻino mucosal i hoʻokumu ʻia e ka puhi a me ka haumia. ʻO kā lākou pale ʻana i nā mea neutrophil chemotactic e hōʻemi i nā pane inflammatory ea i nā maʻi, e hoʻemi ana i ka pinepine o nā exacerbations acute.
ʻO nā peptides antimicrobial (e laʻa, nā derivatives LL37) e hōʻemi i ka hopena o ka maʻi pulmonary i ka cystic fibrosis ma o ka hoʻopau ʻana i nā biofilms Pseudomonas aeruginosa a me ka hoʻoponopono ʻana i ka macrophage phagocytosis. Kāohi lākou i ka hoʻokuʻu nui ʻana o nā mea inflammatory, e hoʻopaneʻe i ka holomua o ka fibrosis pulmonary.
Hoʻopili i ka fibrosis pulmonary
ʻO nā peptides hoʻoponopono Pineal (e laʻa, Pinealon) ke keʻakeʻa i ka hoʻoulu nui ʻana o nā fibroblasts māmā ma o ka hoʻoponopono ʻana i ka hana mitochondrial a me ka hana telomerase, e hōʻemi ana i ka waiho ʻana o ke ʻano I collagen a me fibronectin. I ka bleomycin-induced pulmonary fibrosis models, hoʻemi nui lākou i ka mānoanoa alveolar septal a hoʻomaikaʻi i ka hana o ka māmā.
2. Pūnaehana Cardiovascular: Palekana Vascular a Hoʻoponopono Myocardial
No nā maʻi e like me ke atherosclerosis, myocardial infarction, a me ka pau ʻole o ka naʻau, hana nā mea peptide ma ka hoʻoponopono ʻana i ka angiogenesis, anti-myocardial apoptosis, a me ka hoʻomaikaʻi ʻana i ka metabolism ikehu.
ʻO ka angiogenesis a me ka pale endothelial
ʻO nā peptides Angiogenic e hoʻohālike i ka hana o ka mea ulu endothelial vascular, e hāpai ana i ka hoʻonui ʻana o ka cell endothelial, neʻe, a me ka hoʻokumu ʻana o lumen. I ka maʻi puʻuwai ischemic, hoʻoulu lākou i ka hoʻokumu ʻana i ka collateral circulation e hoʻomaikaʻi i ke koko myocardial. ʻO kā lākou hoʻoulu ʻana o ka vascular endothelial nitric oxide synthase e hoʻonui i ka dilation vascular a hōʻemi i ka hopena o ka hoʻokumu ʻana o ka atherosclerotic plaque.
ʻO nā peptides cardioprotective (e laʻa, Corgaten) e hoʻopaʻa i ka myocardial mitochondrial membranes, ke keʻakeʻa nei i ka hoʻokuʻu ʻana o ka cytochrome C a me ka hoʻōla ala apoptosis. Hoʻemi kēia i ka necrosis cell myocardial ma muli o ka hōʻeha ischemia-reperfusion, hoʻomaikaʻi i ka hana systolic cardiac ma hope o ka myocardial infarction, hoʻemi i ka wahi fibrosis, a hoʻopaneʻe i ka holomua o ka naʻau.
Hoʻoponopono antithrombotic a me lipid
ʻO nā peptides i loaʻa mai i ka RGD ke kāohi i ka hoʻohui platelet ma ke kāohi ʻana i ka hoʻopaʻa ʻana o ka platelet surface integrins i fibrinogen, e lawelawe ana ma ke ʻano he mau molela nui i ka hoʻomohala ʻana i nā lāʻau antithrombotic hou. Aia ko lākou pōmaikaʻi i ka haʻahaʻa haʻahaʻa o ke koko e hoʻohālikelike ʻia me nā anticoagulants kuʻuna.
Kiʻi 2. Nā ʻāpana o ka ʻōnaehana vasopressin e pili ana i ka hoʻoponopono ʻana i ke kahe o ke koko i loko o ka lolo, ka puʻuwai, nā kīʻaha, nā puʻupaʻa, nā māmā a me nā ʻōnaehana digestive. AVP—arginine vasopressin; SNS—pūnaewele puʻuwai aloha; V1aR—vasopressin V1a loaʻa; V1bR—vasopressin V1b loaʻa; V2R—vasopressin V2 loaʻa. Source: ʻO ka puʻuwai ma ke ʻano he pahuhopu o Vasopressin a me nā peptides Cardiovascular ʻē aʻe i ke olakino a me nā maʻi maʻi cardiovascular (2022).
3. Noiʻi hoʻokolohua: Hoʻomohala a me ka hoʻohana ʻana i nā Peptides Mea Hana Pono
I ka lāʻau lapaʻau maʻamau a me ka hoʻomohala ʻana i ka lāʻau lapaʻau, lawelawe ʻia nā mea peptide ma ke ʻano he molekele mea hana pono e holomua i ka noiʻi mīkini pololei a me ka hana hoʻohālike.
ʻO nā hōʻailona ala ala
ʻO kekahi mau peptides (e laʻa, Src kinase inhibitory peptides) e ālai pono i ka hana o nā kinase ʻohana Src, i hoʻohana ʻia e aʻo i nā mīkini hoʻololi hōʻailona i ka hoʻonui ʻana a me ka neʻe ʻana. ʻO kā lākou pilina kiʻekiʻe e hiki ai i ka spatiotemporal ke hoʻoponopono pololei i nā ala kikoʻī.
G protein-coupled receptor (GPCR) ligand peptides (e laʻa, PT141 analogs)
Hoʻohana ʻia kēia mau peptides no ka wehe ʻana i nā GPCR-mediated cellular signal transduction network, e hāʻawi ana i nā hiʻohiʻona no ka nānā ʻana i nā pahuhopu lāʻau i nā maʻi metabolic.
Ka hopena
ʻO ka hoʻohana ʻana i nā mea peptide i nā noi kūikawā ʻē aʻe e hōʻike ana i ka hiki ke hoʻololi a me ka hana hou o kēia mau molekala i nā hiʻohiʻona cross-disciplinary. I loko o ka ʻōnaehana hanu, hāʻawi lākou i ka pale hope-a-hope mai ka hoʻoponopono ʻana o ka mucosal i ka hana fibrosis; i ka cardiology, ua haki lākou i nā bottlenecks therapeutic kuʻuna ma o ka angiogenesis a me ka pale myocardial; i ka noiʻi hoʻokolohua, hana lākou ma ke ʻano he mea hana pololei e holomua i ka loiloi mīkini a me ka ʻike lāʻau. ʻAʻole wale kēia mau noi e hoʻopiha i nā āpau lapaʻau no nā maʻi kikoʻī akā hōʻike pū kekahi i ke kuleana pili o nā mea peptide i ka noiʻi kumu a me ka unuhi lapaʻau.
ʻO nā ʻatikala a me nā ʻike huahana i hāʻawi ʻia ma kēia pūnaewele pūnaewele wale nō no ka hoʻolaha ʻana i ka ʻike a me nā kumu hoʻonaʻauao.
ʻO nā huahana i hāʻawi ʻia ma kēia pūnaewele i manaʻo wale ʻia no ka noiʻi in vitro. Hana ʻia ka noiʻi in vitro (Latin: *i ke aniani*, ʻo ia hoʻi i ka ipu aniani) ma waho o ke kino kanaka. ʻAʻole kēia mau huahana he lāʻau lapaʻau, ʻaʻole i ʻae ʻia e ka US Food and Drug Administration (FDA), a ʻaʻole pono e hoʻohana ʻia no ka pale ʻana, mālama, a hoʻōla paha i kekahi maʻi olakino, maʻi, a i ʻole maʻi. Ua pāpā loa ʻia e ke kānāwai ke hoʻokomo i kēia mau huahana i loko o ke kino kanaka a holoholona paha ma kekahi ʻano.
